Lacey Capps
Family · Brentwood, TNNPI 1164583894
Payments from drug & device makers
Across 167 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$481
- AbbVie$397
- Lilly USA, LLC$386
- AstraZeneca$341
- Esperion Therapeutics, Inc.$245
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$150
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,020100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $481 |
| AbbVie | 23 | $397 |
| Lilly USA, LLC | 19 | $386 |
| AstraZeneca | 21 | $341 |
| Esperion Therapeutics, Inc. | 14 | $245 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $150 |
| Exact Sciences | 7 | $109 |
| Amgen | 6 | $108 |
| Pfizer | 5 | $104 |
| Shield Therapeutics Inc | 5 | $84 |
| GSK | 4 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $70 |
| Boehringer Ingelheim | 4 | $66 |
| Merck | 4 | $63 |
| Advanced Bionics, LLC | 2 | $54 |
| Nevro Corp. | 2 | $49 |
| Axsome Therapeutics, Inc. | 3 | $48 |
| Astellas Pharma US Inc | 1 | $33 |
| Optinose US, Inc. | 1 | $27 |
| Novartis | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $12 |
How this compares
$3,020 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 17 | $32,116 |
| JardianceEmpagliflozin | 26 | $28,815 |
| TrulicityDulaglutide | 15 | $25,072 |
| JanuviaSitagliptin Phosphate | 14 | $15,787 |
| Fluticasone Propionate | 82 | $1,722 |
| Famotidine | 86 | $1,595 |
| Omeprazole | 70 | $1,342 |
| Bromocriptine Mesylate | 12 | $1,038 |
| Atorvastatin Calcium | 122 | $1,015 |
| Azelastine Hcl | 16 | $905 |
| Losartan Potassium | 72 | $864 |
| Mirtazapine | 24 | $771 |
| Levothyroxine Sodium | 91 | $750 |
| Montelukast Sodium | 43 | $685 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $481 | $32,11617 claims |
| Boehringer IngelheimJardiance | $66 | $28,81526 claims |
| Lilly USA, LLCTrulicity | $386 | $25,07215 claims |
| MerckJanuvia | $63 | $15,78714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.
Other family in Brentwood
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.